Molecular profiling of a bladder cancer with very high tumour mutational burden.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
received:
23
01
2024
accepted:
22
02
2024
revised:
16
02
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
The increasing incidence of urothelial bladder cancer is a notable global concern, as evidenced by the epidemiological data in terms of frequency, distribution, as well as mortality rates. Although numerous molecular alterations have been linked to the occurrence and progression of bladder cancer, currently there is a limited knowledge on the molecular signature able of accurately predicting clinical outcomes. In this report, we present a case of a pT3b high-grade infiltrating urothelial carcinoma with areas of squamous differentiation characterized by very high tumor mutational burden (TMB), with up-regulations of immune checkpoints. The high TMB, along with elevated expressions of PD-L1, PD-L2, and PD1, underscores the rationale for developing a personalized immunotherapy focused on the use of immune-checkpoint inhibitors. Additionally, molecular analysis revealed somatic mutations in several other cancer-related genes, including TP53, TP63 and NOTCH3. Mutations of TP53 and TP63 genes provide mechanistic insights on the molecular mechanisms underlying disease development and progression. Notably, the above-mentioned mutations and the elevated hypoxia score make the targeting of p53 and/or hypoxia related pathways a plausible personalized medicine option for this bladder cancer, particularly in combination with immunotherapy. Our data suggest a requirement for molecular profiling in bladder cancer to possibly select appropriate immune-checkpoint therapy.
Identifiants
pubmed: 38688924
doi: 10.1038/s41420-024-01883-x
pii: 10.1038/s41420-024-01883-x
doi:
Types de publication
Journal Article
Langues
eng
Pagination
202Informations de copyright
© 2024. The Author(s).
Références
https://gco.iarc.fr/tomorrow , accessed [28th February 2024].
Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84:176–90.
pubmed: 37198015
doi: 10.1016/j.eururo.2023.03.029
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420–33.
pubmed: 31563503
doi: 10.1016/j.eururo.2019.09.006
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81:75–94.
pubmed: 34511303
doi: 10.1016/j.eururo.2021.08.010
Dyrskjøt L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Prim. 2023;9:58.
pubmed: 37884563
doi: 10.1038/s41572-023-00468-9
McClure MB, Kogure Y, Ansari-Pour N, Saito Y, Chao HH, Shepherd J, et al. Landscape of genetic alterations underlying hallmark signature changes in cancer reveals TP53 aneuploidy-driven metabolic reprogramming. Cancer Res Commun. 2023;3:281–96.
pubmed: 36860655
pmcid: 9973382
doi: 10.1158/2767-9764.CRC-22-0073
Panatta E, Butera A, Celardo I, Leist M, Melino G, Amelio I. p53 regulates expression of nuclear envelope components in cancer cells. Biol Direct. 2022;17:38.
pubmed: 36461070
pmcid: 9716746
doi: 10.1186/s13062-022-00349-3
Patelli G, Zeppellini A, Spina F, Righetti E, Stabile S, Amatu A, et al. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives. Cancer Treat Rev. 2022;104:102351.
pubmed: 35180563
doi: 10.1016/j.ctrv.2022.102351
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.
doi: 10.1038/nature12965
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301.
pubmed: 33863885
pmcid: 8052448
doi: 10.1038/s41467-021-22465-w
Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400:1712–21.
pubmed: 36174585
doi: 10.1016/S0140-6736(22)01188-6
Li Q, Damish AW, Frazier Z, Liu D, Reznichenko E, et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin Cancer Res. 2019;25:977–88.
pubmed: 29980530
doi: 10.1158/1078-0432.CCR-18-1001
Börcsök J, Sztupinszki Z, Bekele R, Gao SP, Diossy M, Samant AS, et al. Identification of a synthetic lethal relationship between nucleotide excision repair deficiency and irofulven sensitivity in urothelial cancer. Clin Cancer Res. 2021;27:2011–22.
pubmed: 33208343
doi: 10.1158/1078-0432.CCR-20-3316
Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82:114–29.
pubmed: 34753771
doi: 10.1158/0008-5472.CAN-21-2362
Ouyang Y, Ou Z, Zhong W, Yang J, Fu S, Ouyang N, et al. FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation. Cancer Res. 2023;83:4030–46.
pubmed: 37768887
pmcid: 10722136
doi: 10.1158/0008-5472.CAN-23-1065
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44–56.
pubmed: 30395155
doi: 10.1093/annonc/mdy495
Panatta E, Butera A, Mammarella E, Pitolli C, Mauriello A, Leist M, et al. Metabolic regulation by p53 prevents R-loop-associated genomic instability. Cell Rep. 2022;41:111568.
pubmed: 36323249
doi: 10.1016/j.celrep.2022.111568
Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593.
pubmed: 30309915
pmcid: 6718162
doi: 10.1126/science.aar3593
Spasova V, Mladenov B, Rangelov S, Hammoudeh Z, Nesheva D, Serbezov D, et al. Clinical impact of copy number variation changes in bladder cancer samples. Exp Ther Med. 2021;22:901.
pubmed: 34257714
pmcid: 8243332
doi: 10.3892/etm.2021.10333
Scimeca M, Bonfiglio R, Urbano N, Cerroni C, Anemona L, Montanaro M, et al. Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition. Urol Oncol. 2019;37:297.e19–e31.
pubmed: 30827759
doi: 10.1016/j.urolonc.2019.02.013
Bonfiglio R, Nardozi D, Scimeca M, Cerroni C, Mauriello A, Bonanno E. PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy. Future Oncol. 2017;13:2129–31.
pubmed: 28984478
doi: 10.2217/fon-2017-0278
Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023;41:1470–91.
pubmed: 36603169
doi: 10.1200/JCO.22.02331
Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:eaax0182.
pubmed: 32001626
pmcid: 7789854
doi: 10.1126/science.aax0182
Salomé B, Sfakianos JP, Ranti D, Daza J, Bieber C, Charap A, et al. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell. 2022;40:1027–43.e9.
pubmed: 36099881
pmcid: 9479122
doi: 10.1016/j.ccell.2022.08.005
Jung J, Heo YJ, Park S. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. J Immunother Cancer. 2023;11:e006454.
pubmed: 37094985
pmcid: 10152061
doi: 10.1136/jitc-2022-006454
Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404–23.
pubmed: 32767764
doi: 10.3322/caac.21631
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun. 2021;26:100296.
pubmed: 33421822
doi: 10.1016/j.ctarc.2020.100296
https://www.clinicaltrials.gov/study/NCT04223856 , accessed [28th February 2024].
Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76:3003–13.
pubmed: 27013195
doi: 10.1158/0008-5472.CAN-15-1313
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, et al. Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin Cancer Res. 2023;29:1496–505.
pubmed: 36534531
doi: 10.1158/1078-0432.CCR-22-1764
Amelio I, Mancini M, Petrova V, Cairns RA, Vikhreva P, Nicolai S, et al. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci USA. 2018;115:E10869–78.
pubmed: 30381462
pmcid: 6243248
doi: 10.1073/pnas.1808314115
Melino G, Memmi EM, Pelicci PG, Bernassola F. Maintaining epithelial stemness with p63. Sci Signal. 2015;8:re9.
pubmed: 26221054
doi: 10.1126/scisignal.aaa1033
Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P, et al. p73 regulates serine biosynthesis in cancer. Oncogene. 2014;33:5039–46.
pubmed: 24186203
doi: 10.1038/onc.2013.456
Oberst A, Malatesta M, Aqeilan RI, Rossi M, Salomoni P, Murillas R, et al. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci USA. 2007;104:11280–5.
pubmed: 17592138
pmcid: 2040890
doi: 10.1073/pnas.0701773104
Ciccarese C, Massari F, Blanca A, Tortora G, Montironi R, Cheng L, et al. Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opin Ther Targets. 2017;21:401–14.
pubmed: 28281901
doi: 10.1080/14728222.2017.1297798
Candi E, Oddi S, Paradisi A, Terrinoni A, Ranalli M, Teofoli P, et al. Expression of transglutaminase 5 in normal and pathologic human epidermis. J Invest Dermatol. 2002;119:670–7.
pubmed: 12230511
doi: 10.1046/j.1523-1747.2002.01853.x
Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, et al. TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022;40:3289–300.
pubmed: 35658479
pmcid: 9553389
doi: 10.1200/JCO.21.02506
Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10:e142–54.
pubmed: 36725119
doi: 10.1016/S2352-3026(22)00355-6
Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci. 2003;28:663–70.
pubmed: 14659698
doi: 10.1016/j.tibs.2003.10.004
Ramal M, Corral S, Kalisz M, Lapi E, Real FX. The urothelial gene regulatory network: understanding biology to improve bladder cancer management. Oncogene. 2024;43:1–21.
pubmed: 37996699
doi: 10.1038/s41388-023-02876-3
Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003;9:5501–7.
pubmed: 14654529
Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, et al. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012;7:e30206.
pubmed: 22253920
pmcid: 3254658
doi: 10.1371/journal.pone.0030206
Cappello A, Tosetti G, Smirnov A, Ganini C, Yang X, Shi Y, et al. p63 orchestrates serine and one carbon metabolism enzymes expression in head and neck cancer. Biol Direct. 2023;18:73.
pubmed: 37946250
pmcid: 10636826
doi: 10.1186/s13062-023-00426-1
Brahim S, Negulescu AM, Geneste C, Schott T, Lin S, Morel LO, et al. Notch3 regulates Mybl2 via HeyL to limit proliferation and tumor initiation in breast cancer. Cell Death Dis. 2023;14:171.
pubmed: 36854682
pmcid: 9975231
doi: 10.1038/s41419-023-05674-7
Zhang YQ, Liang YK, Wu Y, Chen M, Chen WL, Li RH, et al. Notch3 inhibits cell proliferation and tumorigenesis and predicts better prognosis in breast cancer through transactivating PTEN. Cell Death Dis. 2021;12:502.
pubmed: 34006834
pmcid: 8131382
doi: 10.1038/s41419-021-03735-3
Xiu M, Wang Y, Li B, Wang X, Xiao F, Chen S, et al. The role of Notch3 signaling in cancer stemness and chemoresistance: molecular mechanisms and targeting strategies. Front Mol Biosci. 2021;8:694141.
pubmed: 34195229
pmcid: 8237348
doi: 10.3389/fmolb.2021.694141
Wang W, Chen D, Zhu K. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition. J Exp Clin Cancer Res. 2018;37:37.
pubmed: 29475441
pmcid: 6389193
doi: 10.1186/s13046-018-0689-3
Jeong JY, Kang H, Kim TH, Kim G, Heo JH, Kwon AY, et al. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett. 2017;386:168–78.
pubmed: 27887917
doi: 10.1016/j.canlet.2016.11.017
Mathieu M, Cotta-Grand N, Daudelin JF, Thébault P, Labrecque N. Notch signaling regulates PD-1 expression during CD8(+) T-cell activation. Immunol Cell Biol. 2013;91:82–8.
pubmed: 23070399
doi: 10.1038/icb.2012.53
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8:761–73.
pubmed: 28382138
pmcid: 5381164
doi: 10.7150/jca.17648
Giovannini C, Minguzzi M, Baglioni M, Fornari F, Giannone F, Ravaioli M, et al. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Oncotarget. 2014;5:10607–20.
pubmed: 25431954
pmcid: 4279397
doi: 10.18632/oncotarget.2523
Teoh SL, Das S. Notch signalling pathways and their importance in the treatment of cancers. Curr Drug Targets. 2018;19:128–43.
pubmed: 28294046
doi: 10.2174/1389450118666170309143419
Pagliaro L, Marchesini M, Roti G. Targeting oncogenic Notch signaling with SERCA inhibitors. J Hematol Oncol. 2021;14:8.
pubmed: 33407740
pmcid: 7789735
doi: 10.1186/s13045-020-01015-9
https://www.mycancergenome.org/content/gene/notch3/#ref-4 , accessed [28th February 2024].
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.
pubmed: 23945592
pmcid: 3776390
doi: 10.1038/nature12477
Brady SW, Gout AM, Zhang J. Therapeutic and prognostic insights from the analysis of cancer mutational signatures. Trends Genet. 2022;38:194–208.
pubmed: 34483003
doi: 10.1016/j.tig.2021.08.007
Scimeca M, Urbano N, Bonfiglio R, Duggento A, Toschi N, Schillaci O, et al. Novel insights into breast cancer progression and metastasis: a multidisciplinary opportunity to transition from biology to clinical oncology. Biochim Biophys Acta Rev Cancer. 2019;1872:138–48.
pubmed: 31348975
doi: 10.1016/j.bbcan.2019.07.002
Scimeca M, Bonfiglio R, Varone F, Ciuffa S, Mauriello A, Bonanno E. Calcifications in prostate cancer: an active phenomenon mediated by epithelial cells with osteoblast-phenotype. Microsc Res Tech. 2018;81:745–8.
pubmed: 29633435
doi: 10.1002/jemt.23031
Scimeca M, Giocondo R, Montanaro M, Granaglia A, Bonfiglio R, Tancredi V, et al. BMP-2 variants in breast epithelial to mesenchymal transition and microcalcifications origin. Cells. 2020;9:1381.
pubmed: 32498363
pmcid: 7348762
doi: 10.3390/cells9061381
Bonfiglio R, Sisto R, Casciardi S, Palumbo V, Scioli MP, Giacobbi E, et al. Aluminium bioaccumulation in colon cancer, impinging on epithelial-mesenchymal-transition and cell death. Sci Total Environ. 2024;908:168335.
pubmed: 37939965
doi: 10.1016/j.scitotenv.2023.168335
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 2023;30:1097–154.
pubmed: 37100955
pmcid: 10130819
doi: 10.1038/s41418-023-01153-w
Hou P, Fang J, Liu Z, Shi Y, Agostini M, Bernassola F, et al. Macrophage polarization and metabolism in atherosclerosis. Cell Death Dis. 2023;14:691.
pubmed: 37863894
pmcid: 10589261
doi: 10.1038/s41419-023-06206-z
Lodhi T, Song YP, West C, Hoskin P, Choudhury A. Hypoxia and its modification in bladder cancer: current and future perspectives. Clin Oncol (R Coll Radio). 2021;33:376–90.
doi: 10.1016/j.clon.2021.03.001
Zhang Z, Li Q, Li A, Wang F, Li Z, Meng Y, et al. Identifying a hypoxia related score to predict the prognosis of bladder cancer: a study with The Cancer Genome Atlas (TCGA) database. Transl Androl Urol. 2021;10:4353–64.
pubmed: 35070817
pmcid: 8749062
doi: 10.21037/tau-21-569
Augustin RC, Delgoffe GM, Najjar YG. Characteristics of the tumor microenvironment that influence immune cell functions: hypoxia, oxidative stress, metabolic alterations. Cancers (Basel). 2020;12:3802.
pubmed: 33348579
doi: 10.3390/cancers12123802
Fan P, Zhang N, Candi E, Agostini M, Piacentini M, TOR Centre. et al. Alleviating hypoxia to improve cancer immunotherapy. Oncogene. 2023;42:3591–604.
pubmed: 37884747
doi: 10.1038/s41388-023-02869-2
Priami C, Montariello D, De Michele G, Ruscitto F, Polazzi A, Ronzoni S, et al. Aberrant activation of p53/p66Shc-mInsc axis increases asymmetric divisions and attenuates proliferation of aged mammary stem cells. Cell Death Differ. 2022;29:2429–44.
pubmed: 35739253
pmcid: 9751089
doi: 10.1038/s41418-022-01029-5
Lindström MS, Bartek J, Maya-Mendoza A. p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways. Cell Death Differ. 2022;29:972–82.
pubmed: 35444234
pmcid: 9090812
doi: 10.1038/s41418-022-00999-w
Levine AJ. Exploring the future of research in the Tp53 field. Cell Death Differ. 2022;29:893–4.
pubmed: 35383291
pmcid: 9090764
doi: 10.1038/s41418-022-00986-1
El-Saafin F, Bergamasco MI, Chen Y, May RE, Esakky P, Hediyeh-Zadeh S, et al. Loss of TAF8 causes TFIID dysfunction and p53-mediated apoptotic neuronal cell death. Cell Death Differ. 2022;29:1013–27.
pubmed: 35361962
pmcid: 9091217
doi: 10.1038/s41418-022-00982-5
Chen P, Duan X, Li X, Li J, Ba Q, Wang H. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α. Oncogene. 2020;39:2863–76.
pubmed: 32034309
doi: 10.1038/s41388-020-1190-y
Amelio I, Melino G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends Biochem Sci. 2015;40:425–34.
pubmed: 26032560
doi: 10.1016/j.tibs.2015.04.007
de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, et al. The TP53 database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ. 2022;29:1071–3.
pubmed: 35352025
pmcid: 9090805
doi: 10.1038/s41418-022-00976-3
Kennedy MC, Lowe SW. Mutant p53: it’s not all one and the same. Cell Death Differ. 2022;29:983–7.
pubmed: 35361963
pmcid: 9090915
doi: 10.1038/s41418-022-00989-y
Schillaci O, Scimeca M, Toschi N, Bonfiglio R, Urbano N, Bonanno E. Combining diagnostic imaging and pathology for improving diagnosis and prognosis of cancer. Contrast Media Mol Imaging. 2019;2019:9429761.
pubmed: 31354394
pmcid: 6636452
doi: 10.1155/2019/9429761
Scimeca M, Urbano N, Bonfiglio R, Schillaci O, Bonanno E. Management of oncological patients in the digital era: anatomic pathology and nuclear medicine teamwork. Future Oncol. 2018;14:1013–5.
pubmed: 29623724
doi: 10.2217/fon-2017-0698
Bonfiglio R, Di Pietro ML. The impact of oral contraceptive use on breast cancer risk: state of the art and future perspectives in the era of 4P medicine. Semin Cancer Biol. 2021;72:11–8.
pubmed: 33454355
doi: 10.1016/j.semcancer.2020.10.008
Smirnov A, Melino G, Candi E. Gene expression in organoids: an expanding horizon. Biol Direct. 2023;18:11.
pubmed: 36964575
pmcid: 10038780
doi: 10.1186/s13062-023-00360-2
Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction. Cell Cycle. 2012;11:3638–48. https://doi.org/10.4161/cc.21918 .
doi: 10.4161/cc.21918
pubmed: 22935697
pmcid: 3478314
Fazi B, Melino S, De Rubeis S, Bagni C, Paci M, Piacentini M, et al. Acetylation of RTN-1C regulates the induction of ER stress by the inhibition of HDAC activity in neuroectodermal tumors. Oncogene. 2009;28:3814–24.
pubmed: 19668229
doi: 10.1038/onc.2009.233
Sunzini F, De Stefano S, Chimenti MS, Melino S. Hydrogen sulfide as potential regulatory gasotransmitter in arthritic diseases. Int J Mol Sci. 2020;21:1180.
pubmed: 32053981
pmcid: 7072783
doi: 10.3390/ijms21041180
Melino S, Paci M. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach. FEBS J. 2007;274:2986–3002.
pubmed: 17509079
doi: 10.1111/j.1742-4658.2007.05831.x
Aceto A, Dragani B, Melino S, Allocati N, Masulli M, Di Ilio C, et al. Identification of an N-capping box that affects the alpha 6-helix propensity in glutathione S-transferase superfamily proteins: a role for an invariant aspartic residue. Biochem J. 1997;322:229–34.
pubmed: 9078266
pmcid: 1218181
doi: 10.1042/bj3220229
Sabelli R, Iorio E, De Martino A, Podo F, Ricci A, Viticchiè G, et al. Rhodanese-thioredoxin system and allyl sulfur compounds. FEBS J. 2008;275:3884–99.
pubmed: 18616471
doi: 10.1111/j.1742-4658.2008.06535.x
Cabras T, Patamia M, Melino S, Inzitari R, Messana I, Castagnola M, et al. Pro-oxidant activity of histatin 5 related Cu(II)-model peptide probed by mass spectrometry. Biochem Biophys Res Commun. 2007;358:277–84.
pubmed: 17482573
doi: 10.1016/j.bbrc.2007.04.121
Servadei F, Anemona L, Cardellini M, Scimeca M, Montanaro M, Rovella V, et al. The risk of carotid plaque instability in patients with metabolic syndrome is higher in women with hypertriglyceridemia. Cardiovasc Diabetol. 2021;20:98.
pubmed: 33957931
pmcid: 8103747
doi: 10.1186/s12933-021-01277-8
Bonfiglio R, Galli F, Varani M, Scimeca M, Borri F, Fazi S, et al. Extensive histopathological characterization of inflamed bowel in the dextran sulfate sodium mouse model with emphasis on clinically relevant biomarkers and targets for drug development. Int J Mol Sci. 2021;22:2028.
pubmed: 33670766
pmcid: 7923003
doi: 10.3390/ijms22042028
Nepravishta R, Sabelli R, Iorio E, Micheli L, Paci M, Melino S. Oxidative species and S-glutathionyl conjugates in the apoptosis induction by allyl thiosulfate. FEBS J. 2012;279:154–67.
pubmed: 22035263
doi: 10.1111/j.1742-4658.2011.08407.x
Montanaro M, Scimeca M, Anemona L, Servadei F, Giacobbi E, Bonfiglio R, et al. The paradox effect of calcification in carotid atherosclerosis: microcalcification is correlated with plaque instability. Int J Mol Sci. 2021;22:395.
pubmed: 33401449
pmcid: 7796057
doi: 10.3390/ijms22010395
Yang X, Smirnov A, Buonomo OC, Mauriello A, Shi Y, Bischof J, et al. A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency. Cell Death Discov. 2023;9:365.
pubmed: 37783677
pmcid: 10545677
doi: 10.1038/s41420-023-01650-4
Han Y, Rovella V, Smirnov A, Buonomo OC, Mauriello A, Perretta T, et al. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient. Cell Death Discov. 2023;9:370.
pubmed: 37813891
pmcid: 10562433
doi: 10.1038/s41420-023-01651-3
Wang M, Luo W, Jones K, Bian X, Williams R, Higson H, et al. SomaticCombiner: improving the performance of somatic variant calling based on evaluation tests and a consensus approach. Sci Rep. 2020;10:12898.
pubmed: 32732891
pmcid: 7393490
doi: 10.1038/s41598-020-69772-8
Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15:591–4.
pubmed: 30013048
doi: 10.1038/s41592-018-0051-x
Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009;25:2283–5.
pubmed: 19542151
pmcid: 2734323
doi: 10.1093/bioinformatics/btp373
Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2012;28:311–7.
pubmed: 22155872
doi: 10.1093/bioinformatics/btr665
Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 2014;24:1881–93.
pubmed: 25060187
pmcid: 4216928
doi: 10.1101/gr.180281.114
Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28:i333–9.
pubmed: 22962449
pmcid: 3436805
doi: 10.1093/bioinformatics/bts378
Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32:1220–2.
pubmed: 26647377
doi: 10.1093/bioinformatics/btv710
Manders F, Brandsma AM, de Kanter J, Verheul M, Oka R, van Roosmalen MJ, et al. MutationalPatterns: the one stop shop for the analysis of mutational processes. BMC Genomics. 2022;23:134.
pubmed: 35168570
pmcid: 8845394
doi: 10.1186/s12864-022-08357-3
Melino S, Nepravishta R, Bellomaria A, Di Marco S, Paci M. Nucleic acid binding of the RTN1-C C-terminal region: toward the functional role of a reticulon protein. Biochemistry. 2009;48:242–53.
pubmed: 19140693
doi: 10.1021/bi801407w
Melino S, Leo S, Toska Papajani V. Natural hydrogen sulfide donors from Allium sp. as a nutraceutical approach in Type 2 diabetes prevention and therapy. Nutrients. 2019;11:1581.
pubmed: 31336965
pmcid: 6682899
doi: 10.3390/nu11071581
Gallo M, Paludi D, Cicero DO, Chiovitti K, Millo E, Salis A, et al. Identification of a conserved N-capping box important for the structural autonomy of the prion alpha 3-helix: the disease associated D202N mutation destabilizes the helical conformation. Int J Immunopathol Pharm. 2005;18:95–112.
doi: 10.1177/039463200501800111
Huang MN, McPherson JR, Cutcutache I, Teh BT, Tan P, Rozen SG. MSIseq: software for assessing microsatellite instability from catalogs of somatic mutations. Sci Rep. 2015;5:13321.
pubmed: 26306458
doi: 10.1038/srep13321
Oza VH, Fisher JL, Darji R, Lasseigne BN. CINmetrics: an R package for analyzing copy number aberrations as a measure of chromosomal instability. PeerJ. 2023;11:e15244.
pubmed: 37123011
pmcid: 10143595
doi: 10.7717/peerj.15244
Grendár M, Martínek P, Loderer D, Ondič O CNHplus: the chromosomal copy number heterogeneity which respects biological constraints. BioRxiv. https://doi.org/10.1101/2022.09.30.510279 . (2022).
Spurr LF, Touat M, Taylor AM, Dubuc AM, Shih J, Meredith DM, et al. Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021;37:2461–3.
pubmed: 33247715
doi: 10.1093/bioinformatics/btaa980
Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Nat Biotechnol. 2011;29:24–6.
pubmed: 21221095
pmcid: 3346182
doi: 10.1038/nbt.1754